Suppr超能文献

微创表面活性剂治疗与气管插管-表面活性剂给药-拔管用于治疗呼吸窘迫综合征早产儿的比较

Comparison of Minimally Invasive Surfactant Therapy and Intubation-surfactant Administration-extubation in Premature Neonates with Respiratory Distress Syndrome.

作者信息

Rezaei Mehrdad, Abbasi Batool, Najib Khadijehsadat, Ardakani Seyed Mostajab Razavinezhad, Moghtaderi Mozhgan, Mostafavi Sara

机构信息

Neonatal Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Allergy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

出版信息

Oman Med J. 2025 Mar 31;40(2):e730. doi: 10.5001/omj.2025.55. eCollection 2025 Mar.

Abstract

OBJECTIVES

Surfactant therapy is an established treatment for neonatal respiratory distress syndrome (RDS). We sought to compare two administration techniques, intubation-surfactant administration-extubation (INSURE) and minimally invasive surfactant therapy (MIST), for efficacy and safety in premature neonates with RDS.

METHODS

In this randomized clinical trial, premature neonates with RDS admitted to a neonatal intensive care unit in Iran from July to December 2020 were randomly assigned either to INSURE or MIST. In the MIST group, the surfactant was administered during spontaneous breathing via a thin vascular catheter without intubation. In the INSURE group, infants were intubated, surfactant administered, and then extubated. The key outcomes were the frequency of surfactant administration, duration of oxygen support, need for mechanical ventilation in the first 72 hours, and complications arising.

RESULTS

The baseline characteristics of the studied premature neonates (N = 82) were similar between the INSURE (n = 44) and MIST (n = 38) groups. The surfactant treatment time was much shorter for the INSURE group (10.5 ± 17.0 minutes) than for the MIST group (42.0 ± 42.5 minutes; < 0.001). All infants received the first dose of surfactant, and requiring a second dose was obeserved in 17 (38.6%) in the INSURE group and 18 (47.4%) in the MIST group ( 0.400). There were no significant differences between the groups in the incidence of intraventricular hemorrhage, bronchopulmonary dysplasia, patent ductus arteriosus, pneumothorax, pulmonary hemorrhage, or disseminated intravascular coagulation. The duration of nasal continuous positive airway pressure and the need for mechanical ventilation were also similar.

CONCLUSIONS

Both INSURE and MIST techniques are effective and safe for administering surfactant therapy to premature infants with RDS, with no significant differences in outcomes or complications.

摘要

目的

表面活性剂疗法是治疗新生儿呼吸窘迫综合征(RDS)的既定疗法。我们试图比较两种给药技术,即插管-表面活性剂给药-拔管(INSURE)和微创表面活性剂疗法(MIST),用于患有RDS的早产儿的疗效和安全性。

方法

在这项随机临床试验中,2020年7月至12月入住伊朗一家新生儿重症监护病房的患有RDS的早产儿被随机分配至INSURE组或MIST组。在MIST组中,表面活性剂通过细血管导管在自主呼吸时给药,无需插管。在INSURE组中,婴儿先插管,给予表面活性剂,然后拔管。主要结局包括表面活性剂给药频率、氧支持持续时间、头72小时内机械通气需求以及出现的并发症。

结果

所研究的早产儿(N = 82)的基线特征在INSURE组(n = 44)和MIST组(n = 38)之间相似。INSURE组的表面活性剂治疗时间(10.5±17.0分钟)比MIST组(42.0±42.5分钟;P<0.001)短得多。所有婴儿均接受了第一剂表面活性剂,INSURE组有17例(38.6%)、MIST组有18例(47.4%)需要第二剂表面活性剂(P = 0.400)。两组在脑室内出血、支气管肺发育不良、动脉导管未闭、气胸、肺出血或弥散性血管内凝血的发生率方面无显著差异。鼻持续气道正压通气的持续时间和机械通气需求也相似。

结论

INSURE和MIST技术在给患有RDS的早产儿进行表面活性剂治疗时均有效且安全,在结局或并发症方面无显著差异。

相似文献

9
Non-invasive high-frequency ventilation in newborn infants with respiratory distress.新生儿呼吸窘迫的无创高频通气。
Cochrane Database Syst Rev. 2024 May 2;5(5):CD012712. doi: 10.1002/14651858.CD012712.pub2.

本文引用的文献

1
Timing of surfactant treatment in respiratory distress syndrome.呼吸窘迫综合征中表面活性剂治疗的时机
Semin Fetal Neonatal Med. 2023 Dec;28(6):101495. doi: 10.1016/j.siny.2023.101495. Epub 2023 Nov 22.
2
Surfactant delivery strategies to prevent bronchopulmonary dysplasia.表面活性物质递送策略预防支气管肺发育不良。
Semin Perinatol. 2023 Oct;47(6):151813. doi: 10.1016/j.semperi.2023.151813. Epub 2023 Sep 9.
6
Guidelines for surfactant replacement therapy in neonates.新生儿表面活性剂替代疗法指南
Paediatr Child Health. 2021 Feb 1;26(1):35-49. doi: 10.1093/pch/pxaa116. eCollection 2021 Feb.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验